Loading
A phase 2 trial of TQB2102 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer is a phase 2 interventional study registered as NCT06452706 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 42 participants planned, started 2024-11-14 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2102 for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/